The stock of Zomedica Corp. (AMEX:ZOM) decreased by $0.0 on Monday to finish at $0.20, up 1.30 percent. The last five days have seen an average of 4,814,240 shares of common stock traded. 6 times new highs were reached in the current year, with a gain of $0.0397. The average number of shares traded over the last 20 days was 4,241,810, while the average volume over the last 50 days totaled 4,303,432.
ZOM stock dropped -4.12% since last month. On 08/14/23, the company’s shares reached a one-month low of $0.1937. The stock touched a high of $0.38 on 01/18/23, after rallying from a low of $0.15 in 52 weeks. The price of ZOM stock has risen by 24.36% or $0.0397 this year, reaching a new high 6 times. Still, the stock price is down -46.63% from the 52-week high.
Insider Transactions
ZOM stock investors should be aware that Zomedica Corp. (ZOM) stock had its last reported insider trading activity 81 days ago on May 26. On May 26, CEO HEATON LARRY C II acquired 100,000 shares at $0.19 each. This transaction resulted in the insider spending $19,090. On May 25, POWERS JOHNNY D added 100,000 shares at a price of US$0.19. After the transaction, the insider now owns 1,600,000 shares.
Valuation Metrics
Beta for the stock is 0.97. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 9.94, the price-to-book (PB) ratio of 0.78.
Financial Health
For the three months ended June 29, Zomedica Corp.’s quick ratio was 18.90, while its current ratio was 19.40, indicating its ability to pay off its debt. As far as profitability goes, gross margin for the trailing twelve months is 71.30% percent. Based on annual data, it had gross profit of $13.65 million and revenue of $18.93 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. There was a -7.30% return on investment (ROI) in the past year.
Earnings Surprise
According to Zomedica Corp.’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $5.05 million, while revenues rose by 15.84% to $5.48 million. It was predicted that Zomedica Corp.’s quarterly earnings would be $0, but it ended up being $0. EBITDA was -$5.87 million for the quarter. At the end of Zomedica Corp.’s most recent quarter ended June 29, its liabilities totaled 15.3 million, while its total debt was $1.42 million. Equity owned by shareholders amounts to $979.95 million.
Technical Picture
Here’s a quick look at Zomedica Corp.’s (ZOM) price momentum from a technical perspective. As of 14 August, the RSI 9-day stood at 43.74%, suggesting the stock is Neutral, with a 42.81% historical volatility rate.
The stochastic %K and %D were 28.99% and 29.73% respectively, while the average true range (ATR) was 0.0105. Based on the 14-day stochastic reading of 34.22%, the RSI (14) reading is 46.09%. On the 9-day MACD Oscillator, the stock is at -0.0041.
Analyst Ratings
In its analyst report released on January 06, 2023, Dawson James began covering Zomedica Corp. (AMEX: ZOM). The stock was rated as a Buy by the brokerage firm. Analysts have assigned Zomedica Corp. (ZOM) an Buy rating. ZOM is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 1 other recommend it as a buy.
What is ZOM’s price target for the next 12 months?
The current consensus forecast for the stock is between $0.44 and $0.44, with a median target price of $0.44. In analyzing these forecasts, the average price target given by analysts for Zomedica Corp. (ZOM) is $0.44.
